{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-124000","form_type":"8-K","ticker":"ZURA","cik":"0001855644","company_name":"Zura Bio Ltd","filed_at":"2023-12-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.126603+00:00","generated_at":"2026-06-07T17:24:02.200861+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Zura Bio appoints Dr. Kiran Nistala as EVP, effective Nov 27, 2023","bullets":["Dr. Nistala appointed Executive Vice President, effective November 27, 2023.","Annual base salary of GBP £320,000; eligible for discretionary bonus targeting 40% of base.","Company will recommend grant of 350,000 share options under 2023 Equity Incentive Plan.","Options vest 1/4 on first anniversary, then 1/36 monthly over 36 months; full vest at 4 years.","Dr. Nistala previously VP late-stage clinical development at AstraZeneca; also held senior roles at GSK."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-124000","json":"https://secwatch.observer/filing/0001104659-23-124000.json","markdown":"https://secwatch.observer/filing/0001104659-23-124000.md","text":"https://secwatch.observer/filing/0001104659-23-124000.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855644/000110465923124000/0001104659-23-124000-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855644/000110465923124000/tm2332309d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T17:24:02.200861+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1d8bea0f02","claim":"Dr. Kiran Nistala was appointed as Executive Vice President at Zura Bio Ltd.","evidence_excerpt":"On November 30, 2023, Zura Bio Limited (the “Company”) appointed Dr. Kiran Nistala as Executive Vice President, effective as of November 27, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855644/000110465923124000/0001104659-23-124000-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}